Hims, Hers Health
UnitedHealth declines following a report that the Justice Department has been investigating the company’s Medicare billing ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s lon ...
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results